| Trademark Snap Shot ITU Unit Action (Table presents the data on ITU Unit Action) |
|||
OVERVIEW |
|||
| SERIAL NUMBER | 88751607 | FILING DATE | 01/08/2020 |
| REG NUMBER | 0000000 | REG DATE | N/A |
| REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
| INTL REG # | N/A | INTL REG DATE | N/A |
| TM ATTORNEY | OWCZARSKI, KAREN ESTIL |
L.O. ASSIGNED | O20-NOT FOUND |
PUB INFORMATION |
|||
| RUN DATE | 02/08/2023 | ||
| PUB DATE | 06/09/2020 | ||
| STATUS | 734-FIFTH EXTENSION - GRANTED | ||
| STATUS DATE | 02/07/2023 | ||
| LITERAL MARK ELEMENT | LIVIMMUNE | ||
| DATE ABANDONED | N/A | DATE CANCELLED | N/A |
| SECTION 2F | NO | SECTION 2F IN PART | NO |
| SECTION 8 | NO | SECTION 8 IN PART | NO |
| SECTION 15 | NO | REPUB 12C | N/A |
| RENEWAL FILED | NO | RENEWAL DATE | N/A |
| DATE AMEND REG | N/A | ||
FILING BASIS |
|||||
| FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
| 1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
| 1 (b) | YES | 1 (b) | YES | 1 (b) | NO |
| 44D | NO | 44D | NO | 44D | NO |
| 44E | NO | 44E | NO | 44E | NO |
| 66A | NO | 66A | NO | ||
| NO BASIS | NO | NO BASIS | NO | ||
MARK DATA |
|
| STANDARD CHARACTER MARK | YES |
| LITERAL MARK ELEMENT | LIVIMMUNE |
| MARK DRAWING CODE | 4-STANDARD CHARACTER MARK |
| COLOR DRAWING FLAG | NO |
CURRENT OWNER INFORMATION |
|
| PARTY TYPE | 20-OWNER AT PUBLICATION |
| NAME | CytoDyn Inc. |
| ADDRESS | 1111 Main Street, Suite 660 Vancouver, WA 98660 |
| ENTITY | 03-CORPORATION |
| CITIZENSHIP | Delaware |
GOODS AND SERVICES |
|
| INTERNATIONAL CLASS | 005 |
| DESCRIPTION TEXT | Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor |
| INTERNATIONAL CLASS | 042 |
| DESCRIPTION TEXT | Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor |
| INTERNATIONAL CLASS | 044 |
| DESCRIPTION TEXT | Providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19 |
GOODS AND SERVICES CLASSIFICATION |
|||||||
| INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
| INTERNATIONAL CLASS | 042 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
| INTERNATIONAL CLASS | 044 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
| CHANGE IN REGISTRATION | NO |
| PSEUDO MARK | LIV IMMUNE; LIVE IMMUNE |
PROSECUTION HISTORY |
||||
| DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
| 02/08/2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 040 |
| 02/07/2023 | EX5G | S | SOU EXTENSION 5 GRANTED | 039 |
| 01/11/2023 | EXT5 | S | SOU EXTENSION 5 FILED | 038 |
| 01/26/2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | 037 |
| 01/11/2023 | EEXT | I | TEAS EXTENSION RECEIVED | 036 |
| 06/28/2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 035 |
| 06/24/2022 | EX4G | S | SOU EXTENSION 4 GRANTED | 034 |
| 06/24/2022 | EXT4 | S | SOU EXTENSION 4 FILED | 033 |
| 06/24/2022 | EEXT | I | TEAS EXTENSION RECEIVED | 032 |
| 02/01/2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 031 |
| 01/28/2022 | EX3G | S | SOU EXTENSION 3 GRANTED | 030 |
| 01/28/2022 | EXT3 | S | SOU EXTENSION 3 FILED | 029 |
| 01/28/2022 | EEXT | I | TEAS EXTENSION RECEIVED | 028 |
| 07/15/2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 027 |
| 07/13/2021 | EX2G | S | SOU EXTENSION 2 GRANTED | 026 |
| 07/13/2021 | EXT2 | S | SOU EXTENSION 2 FILED | 025 |
| 07/13/2021 | EEXT | I | TEAS EXTENSION RECEIVED | 024 |
| 01/12/2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 023 |
| 01/08/2021 | EX1G | S | SOU EXTENSION 1 GRANTED | 022 |
| 01/08/2021 | EXT1 | S | SOU EXTENSION 1 FILED | 021 |
| 01/08/2021 | EEXT | I | TEAS EXTENSION RECEIVED | 020 |
| 08/04/2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 019 |
| 06/09/2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 018 |
| 06/09/2020 | PUBO | A | PUBLISHED FOR OPPOSITION | 017 |
| 05/20/2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 016 |
| 05/04/2020 | ALIE | A | ASSIGNED TO LIE | 015 |
| 04/24/2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | 014 |
| 04/24/2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | 013 |
| 04/24/2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 012 |
| 04/24/2020 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | 011 |
| 04/24/2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | 010 |
| 04/22/2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 009 |
| 04/21/2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 008 |
| 04/21/2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 007 |
| 03/28/2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 006 |
| 03/28/2020 | GNRT | F | NON-FINAL ACTION E-MAILED | 005 |
| 03/28/2020 | CNRT | R | NON-FINAL ACTION WRITTEN | 004 |
| 03/26/2020 | DOCK | D | ASSIGNED TO EXAMINER | 003 |
| 01/13/2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | 002 |
| 01/11/2020 | NWAP | I | NEW APPLICATION ENTERED | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
| ATTORNEY | Jared M. Barrett |
| CORRESPONDENCE ADDRESS | Jared M. Barrett SEED IP LAW GROUP LLP 701 FIFTH AVENUE, SUITE 5400 SEATTLE, WA 98104 |
| DOMESTIC REPRESENTATIVE | NONE |
PRIOR OWNER INFORMATION |
|
| PARTY TYPE | 10-ORIGINAL APPLICANT |
| NAME | CytoDyn Inc. |
| ADDRESS | Suite 660 1111 Main Street Vancouver, WA 98660 |
| ENTITY | 03-CORPORATION |
| CITIZENSHIP | Delaware |